Search | Clinical Trials Finder

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: ASTX727; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndromes
Interventions: KPT-8602, Inqovi, Bone marrow aspirate, Bone marrow biopsy, ECG; Drug · Procedure · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Myelodysplastic Syndrome
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Enasidenib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 142
States / cities: Berkeley, California • Irvine, California • Orange, California + 118 more

Conditions: Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
Interventions: Belinostat, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Guadecitabine, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 39
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 32 more

Conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Decitabine and Cedazuridine, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndromes
Interventions: DEC-C, MyeloSeq-HD; Drug · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Myelodysplastic Syndrome, MDS
Interventions: ASTX727 Dose Escalation, ASTX727 Dose Confirmation, ASTX727 Fixed-Dose Combination; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 9 more

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Hodgkin Lymphoma
Interventions: Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Nivolumab, Positron Emission Tomography; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Duarte, California • Sacramento, California + 6 more

Conditions: Solid Tumor
Interventions: Decitabine, Cedazuridine; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Baltimore, Maryland

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 10
States / cities: Phoenix, Arizona • Costa Mesa, California • Orange, California + 7 more

Conditions: Systemic Mastocytosis With an Associated Hematologic Neoplasm
Interventions: Avapritinib, Decitabine, Decitabine/Cedazuridine; Drug · Combination Product
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Phoenix, Arizona • Palo Alto, California • Tampa, Florida + 4 more

Conditions: Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage III, Merkel Cell Carcinoma, Stage IV
Interventions: ASTX727 + retifanlimab; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Decitabine and Cedazuridine, Enasidenib, Ivosidenib, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, PALB2 Gene Mutation, Checkpoint Kinase 2 Gene Mutation, ATM Gene Mutation
Interventions: Olaparib, ASTX727; Drug
Lead sponsor: Varun Monga, MBBS; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Myelodysplastic Syndromes
Interventions: Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253, Bone Marrow Biopsy, Bone Marrow Aspiration, ECG; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm
Interventions: Pacritinib, Decitabine, Decitabine and Cedazuridine, Azacitidine, Survey Administration, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy; Drug · Other · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Venetoclax; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 33
States / cities: Phoenix, Arizona • Costa Mesa, California • Irvine, California + 25 more

Conditions: Metastatic Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Tumor
Interventions: Talazoparib, ASTX727; Drug
Lead sponsor: Kathy Miller; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Indianapolis, Indiana • Winston-Salem, North Carolina

Conditions: Castration-Resistant Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Decitabine and Cedazuridine, Enzalutamide; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine, Decitabine and Cedazuridine, Filgrastim, Imaging Procedure, Lumbar Puncture; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 9 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: ASTX727; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma, BRCA1-Associated Protein-1 (BAP1) Mutations, Early-stage BAP1-associated Malignancies
Interventions: Decitabine/cedazuridine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cytarabine, Daunorubicin, Decitabine and Cedazuridine, Venetoclax; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Birmingham, Alabama • New Haven, Connecticut • Buffalo, New York + 3 more

Conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Interventions: ASTX727 + Day 2 Food, ASTX727 + Day 4 Food; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Buffalo, New York • Canton, Ohio • Nashville, Tennessee + 1 more

Search by objective public record fields.

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia

Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Avapritinib With Decitabine in Patients With SM-AHN

ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

BMS-986253 in Myelodysplastic Syndromes

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

Effect of Food on Blood Levels of ASTX727